UruguayTuberculosis profile
Population  2015 3.4 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.069 (0.065–0.073) 2 (1.9–2.1)
Mortality (HIV+TB only) 0.026 (<0.01–0.06) 0.75 (0.16–1.8)
Incidence  (includes HIV+TB) 1 (0.89–1.2) 30 (26–35)
Incidence (HIV+TB only) 0.16 (0.14–0.19) 4.7 (4–5.5)
Incidence (MDR/RR-TB)** <0.01 (<0.01–0.014) 0.21 (0.03–0.41)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.041 (0.025–0.057) 0.31 (0.19–0.42) 0.35 (0.22–0.48)
Males 0.039 (0.027–0.052) 0.65 (0.51–0.79) 0.69 (0.54–0.84)
Total 0.08 (0.061–0.1) 0.95 (0.87–1) 1 (0.89–1.2)
TB case notifications, 2015  
Total cases notified 909
Total new and relapse 900
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 93%
          - % pulmonary 91%
          - % bacteriologically confirmed among pulmonary 75%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.06–0.13)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 131 16%
          - on antiretroviral therapy 67 51%
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  4
(0–9)
Estimated % of TB cases with MDR/RR-TB 0.55% (0.11–1.6) 0% (0–17)  
% notified tested for rifampicin resistance 72% 69% 649
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 3, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 3, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 75% 843
Previously treated cases, excluding relapse, registered in 2014 88% 26
HIV-positive TB cases, all types, registered in 2014 51% 130
MDR/RR-TB cases started on second-line treatment in 2013 100% 1
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) 4
Funding source: 100% domestic,  international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-09 Data: www.who.int/tb/data